Dose expansion phase (Phase II) : Low-dose group:basic treatment loaded with RY_SW01 cell injection 1.0×10^6 cells /kg

RY_SW01 Safety, tolerability and efficacy of Cellular Injection in the treatment of active lupus nephritis. Safety, Tolerability and Efficacy of Cellular Injection in the Treatment of Active Lupus Nephritis Multicenter Phase I/II Clinical Trial Protocol

Multi-center Phase I/II Clinical Study Protocol for the Safety, Tolerability and Efficacy of RY_SW01 Cell Injection in the Treatment of Systemic Sclerosis